Benefits of inhaled nitric oxide therapy for pregnant patients with COVID-19

August 26, 2020

BOSTON - Inhaled nitric oxide (NO) can be a valuable adjunct respiratory therapy for pregnant women with severe and critical COVID-19, a team of researchers from Massachusetts General Hospital (MGH) has found. The delivery of the therapeutic gas to six COVID-19 pregnant patients admitted to MGH, as described in a paper in Obstetrics & Gynecology, resulted in a rapid and sustained improvement in cardiopulmonary function and decreased inflammation. The resolution of viral infection within 22 days was observed in five of the six patients, findings that could have important implications for treating viruses like Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

"We noted rapid relief from breathlessness in these patients, with lower respiratory rate and better oxygenation after mask administration of high concentration nitric oxide, with no adverse side effects," says Lorenzo Berra, MD, investigator in the Department of Anaesthesia, Critical Care and Pain Medicine at MGH, and the corresponding author of the study. "In addition, inflammatory markers showed a rapid decrease after breathing nitric oxide and five of the six patients in our study showed viral clearance from nasopharyngeal swabs by 22 days after COVID-19 diagnosis. All patients were discharged in stable condition from the hospital. We found these results to be very encouraging."

Inhaled nitric oxide acts as a selective pulmonary vasodilator, increasing oxygenation by dilating or opening constricted blood vessels, especially in more well-ventilated areas of the lung, thereby improving intrapulmonary shunt fraction. Nitric oxide was approved by the U.S. Food and Drug Administration (FDA) in 1999 for the treatment of persistent pulmonary hypertension in newborns. Since then, NO has also been used off-label for many pediatric and adult clinical applications, including pulmonary hypertension in pregnancy, post-cardiac surgery, lung transplantation and acute respiratory distress syndrome (ARDS). The MGH study is the first to investigate the role of inhaled NO in pregnant people with COVID-19.

A recent report from the Centers for Disease Control and Prevention (CDC) suggests that pregnant women with COVID-19 are more likely to be hospitalized, are at increased risk of being admitted to the intensive care unit, and more often require mechanical ventilation compared to nonpregnant women. The lack of effective treatments for patients with severe or critical COVID-19 respiratory symptoms prompted a group of physicians from MGH to form an interdisciplinary team to offer pregnant women a novel treatment with inhaled NO to prevent progressive respiratory failure. Between April and June 2020, six hospitalized pregnant COVID-19 patients were given NO therapy. Each treatment was started within 48 hours of admission at a high but still safe dosage of 160 to 200 parts per million (ppm) of inhaled NO for 30 to 60 minutes twice-a-day.

"Even at that dosage, nitric oxide is easy to use and appears well tolerated," says Bijan Safaee Fakhr, MD, an investigator in the Department of Anaesthesia, Critical Care and Pain Medicine at MGH and lead author of the article. "We found that nitric oxide inhalation therapy provided rapid relief of shortness of breath in these patients and that their respiratory rates decreased." Moreover, he notes that three of the six women delivered four babies, including a set of twins, while in the hospital, and that each infant tested negative for COVID-19 and remained in good condition 28 days after maternal admission. These findings suggested to Safaee Fakhr that inhaled NO could result in improved placental oxygenation by improving maternal oxygenation.

The MGH physicians were further intrigued by the potential antiviral activity of inhaled NO in patients with COVID-19. Berra, who is also an associate professor of Anesthesia at Harvard Medical School cited a group of clinicians in China who, during the 2003-2004 SARS outbreak, administered inhaled NO to infected patients and reported that their chest x-ray findings cleared rapidly (Chen et al. Clin Infect Dis. 2004;39(10):1531-5). "Because of the genetic similarities between Coronavirus SARS-CoV-1 (SARS) and CoV-2 (COVID-19), we decided to use high-dose nitric oxide to prevent viral replication," Berra explains. What the physicians learned was that five of the six patients in their cohort who received inhaled NO but no other antiviral medication while in the hospital were clear of the virus, as shown by two negative nasopharyngeal swabs obtained after 9 to 22 days from treatment initiation.

"Additional randomized clinical trials are needed to confirm the antiviral effects and definitively determine the efficacy of inhaled nitric oxide on SARS-CoV-2," says Berra. "Irrespective of that, the cardiopulmonary, anti-inflammatory, and possible mild bronchodilatory effects of NO, coupled with its safety profile, offer clear evidence to support using high dose NO therapy for respiratory failure in pregnant women to combat a still unknown disease like COVID-19."
-end-
Other study co-authors include maternal-fetal medicine physicians William Barth Jr., MD, and Anjali Kaimal, MD, both from the Department of Obstetrics and Gynecology, at MGH; Robert Kacmarek, PhD, director of Respiratory Care at MGH and professor of Anesthesiology at Harvard Medical School; and Warren Zapol, MD, emeritus anesthesiologist-in-chief at MGH.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and departments. In August 2019 the MGH was named #6 in the nation by U.S. News & World Report in its list of "America's Best Hospitals."

Massachusetts General Hospital

Related Critical Care Articles from Brightsurf:

Six ways primary care "medical homes" are lowering health care spending
New analysis of 394 U.S. primary care practices identifies the aspects of care delivery that are associated with lower health care spending and lower utilization of emergency care and hospital admissions.

New strategies suggested for critical heart care in the ICU
Critically ill heart patients are at increased risk of complications that are potentially preventable and associated with death, longer hospital stays and higher costs.

Capital funding of health care in Canada is critical, yet declined in last 20 years
Capital funding of health care, used to build new hospitals, redesign or upgrade existing facilities and invest in new technologies, has declined in Canada over the last 20 years, according to an analysis in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191126.

Mortality of mechanically ventilated COVID-19 patients is lower than previously reported reveals study in Critical Care Medicine
An online first study published in Critical Care Medicine indicates the actual mortality rate of adults with critical illness from COVID-19 is less than what was previously reported.

COVID-19 critical care bed modelling study: potential shortage in Canada
A national modelling paper predicting the number of available ICU beds across Canada during the COVID-19 pandemic suggests that self-isolation will likely not be enough to keep demand from exceeding supply.

Covid-19 tool allows health leaders to plan for critical care surge
The challenges of COVID-19 will require hospital leaders, practitioners and regional officials to adopt drastic measures that challenge the standard way of providing care.

Critical care surgery team develops blueprint for essential operations during COVID-19
To help guide hospital surgery departments through this crisis, the acute surgery division at Atrium Health's Carolinas Medical Center in Charlotte, N.C., has developed a tiered plan for marshaling limited resources.

Study: Critical care improvements may differ depending on hospital's patient population
A new study led by researchers at Beth Israel Deaconess Medical Center reveals that while critical care outcomes in ICUs steadily improved over a decade at hospitals with few minority patients, ICUs with a more diverse patient population did not progress comparably.

Study finds disparity in critical care deaths between non-minority and minority hospitals
While deaths steadily declined over a decade in intensive care units at hospitals with few minority patients, in ICUs with large numbers of minority patients, there was less improvement, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Hospital critical care resuscitation unit improves patients' chances of survival
Patients with acutely life-threatening health conditions who were treated in the innovative Critical Care Resuscitation Unit (CCRU) received faster treatment and had better health outcomes, including a 36 percent lower risk of dying than those who were transferred from a hospital's emergency department then evaluated and treated in a traditional intensive care unit, according to a recent study in the Journal of Emergency Medicine conducted by researchers at the University of Maryland School of Medicine.

Read More: Critical Care News and Critical Care Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.